A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Depemokimab (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms AGILE
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 11 Mar 2025 Planned End Date changed from 22 May 2025 to 19 May 2025.
- 11 Mar 2025 Planned primary completion date changed from 22 May 2025 to 19 May 2025.
- 16 Jul 2024 Planned End Date changed from 7 May 2025 to 22 May 2025.